Table 2 Comparation between derivation and validation cohorts
|
Derivation cohort (n = 554) |
Validation cohort (n = 291) | p-value | |
|---|---|---|---|
| Sex (male) | 267 (48.2%) | 153 (52.6%) | 0.23 |
| Age (years) | 60.43 ± 14.95 | 59.32 ± 16.30 | 0.33 |
| Heart rate (beats/min) | 86.11 ± 17.76 | 87.46 ± 17.89 | 0.30 |
| Systolic pressure (mmHg) | 126.92 ± 18.27 | 125.30 ± 18.09 | 0.22 |
| RV dysfunction | 161 (29.0%) | 79 (27.1%) | 0.56 |
| c-Tn I (μg/L) | 0.11 ± 0.54 | 0.10 ± 0.29 | 0.79 |
| NT-pro BNP (pg/mL) | 1638.25 ± 3958.77 | 1373.61 ± 2980.96 | 0.28 |
| CPA embolism | 141 (25.5%) | 68 (23.4%) | 0.50 |
| Saddle-CPA embolism | 38 (6.9%) | 24 (8.2%) | 0.46 |
| RV short-axis diameter (mm) | 39.26 ± 7.605 | 39.11 ± 6.97 | 0.77 |
| LV short-axis diameter (mm) | 40.58 ± 7.65 | 41.08 ± 7.52 | 0.35 |
| RV4-chamber diameter (mm) | 36.22 ± 7.21 | 36.68 ± 7.68 | 0.41 |
| LV 4-chamber diameter (mm) | 39.50 ± 7.26 | 39.41 ± 7.55 | 0.86 |
| RA 4-chamber diameter (mm) | 45.50 ± 9.38 | 45.32 ± 9.27 | 0.79 |
| LA 4-chamber diameter (mm) | 34.95 ± 8.38 | 34.61 ± 8.77 | 0.58 |
| RV/LV short-axis diameter ratio | 1.00 ± 0.31 | 0.98 ± 0.27 | 0.34 |
| RV/LV 4-chamber diameter ratio | 0.95 ± 0.28 | 0.97 ± 0.35 | 0.37 |
| RA/LA 4-chamber diameter ratio | 1.39 ± 0.52 | 1.40 ± 0.51 | 0.76 |
| Bova score | |||
| Low risk | 445 (80.3%) | 236 (81.1%) | 0.79 |
| Intermediate-low risk | 66 (11.9%) | 36 (12.3%) | 0.85 |
| Intermediate-high risk | 43 (7.8%) | 19 (6.5%) | 0.51 |
| 2019 ESC algorithm | |||
| Low risk | 330 (59.6%) | 173 (59.5%) | 0.97 |
| Intermediate-low risk | 112(20.2%) | 60 (20.6%) | 0.89 |
| Intermediate-high risk | 112(20.2%) | 58 (19.9%) | 0.92 |
| Adverse outcomes | 54(9.7%) | 27(9.3%) | 0.83 |